The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Abstract
This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues ("The Price of Innovation"), using their published cost estimates along with information on success rates and durations from a publicly available data set. For drugs entering human clinical trials for the first time between 1989 and 2002, the paper estimated the cost per new drug to be 868 million dollars. However, our estimates vary from around 500 million dollars to more than 2,000 million dollars, depending on the therapy or the developing firm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery
Henderson, R., & Cockburn, I. (1996) · The RAND Journal of Economics · doi:10.2307/2555791 · Cited by 1,388
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1995) · PharmacoEconomics · doi:10.2165/00019053-199507020-00007 · Cited by 169
Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates
Berndt, E. R., Gottschalk, A. H. B., Philipson, T., & Strobeck, M. W. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1774 · Cited by 106
R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
DiMasi, J. A., Grabowski, H. G., & Vernon, J. (1995) · International Journal of the Economics of Business · doi:10.1080/758519309 · Cited by 73
Cited by
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
Tolerance for Failure and Corporate Innovation
Tian, X., & Wang, T. Y. (2014) · Review of Financial Studies · doi:10.1093/rfs/hhr130 · Cited by 993
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676
Metadata
- Authors
- Adams, C. P., & Brantner, V. V.
- Venue
- Health Affairs
- Publisher
- Health Affairs Publishing, LLC
- Published
- 2006-03
- Volume
- 25
- Issue
- 2
- Pages
- 420-428
- ISSN
- 0278-2715 (ISSN-L)
- 1544-5208
- OpenAlex
- W2166209362
- Cited by
- 907
- References
- 5
- FWCI
- 89.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.